STOCK TITAN

Perspective Therapeutics: Trust buys 15,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. director Robert F. Williamson III reported that the RFW3 Revocable Trust purchased 15,000 common shares at $0.80 per share on November 18, 2026. The trust held 68,473 shares after the purchase. Williamson separately reported 115,271 shares held directly. No Rule 10b5-1 plan is reported for the purchase.

Insider Williamson Robert F III
Role Director
Bought 15,000 shs ($12K)
Increase in Position 28.1%
Type Security Shares Price Value
Purchase Common Stock 15,000 $0.80 $12K
Holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 68,473 shares (Indirect, RFW3 Revocable Trust); Common Stock — 115,271 shares (Direct)
Holdings Before and After: Common Stock, 53,473 to 68,473 shares (Indirect, RFW3 Revocable Trust)
Other Insiders: 4 other insiders reported open-market purchases of this stock in the 30 days up to this filing.
Common shares purchased 15,000 shares Purchased by the RFW3 Revocable Trust on November 18, 2026
Purchase price $0.80 per share RFW3 Revocable Trust purchase on November 18, 2026
Shares held by RFW3 Revocable Trust 68,473 shares Following the purchase on November 18, 2026
Shares held directly 115,271 shares Reported by Robert F. Williamson III on November 18, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CATX shares did Robert F. Williamson III buy and at what price?

The RFW3 Revocable Trust purchased 15,000 shares at $0.80 per share on November 18, 2026. The trust held 68,473 shares after the purchase. No Rule 10b5-1 plan is reported for the purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williamson Robert F III

(Last)(First)(Middle)
C/O PERSPECTIVE THERAPEUTICS, INC.
2401 ELLIOTT AVENUE, SUITE 320

(Street)
SEATTLE WASHINGTON 98121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026P15,000A$0.868,473IRFW3 Revocable Trust
Common Stock115,271D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ Robert F. Williamson, III by Chris Nenno, as Attorney-in-Fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading